Published in Blood on February 15, 1992
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol (2004) 1.00
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. EBioMedicine (2015) 0.94
The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates. Br J Cancer (1995) 0.75
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell (1994) 9.73
All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 9.68
The generation of a ColE1-Apr cloning vehicle which allows detection of inserted DNA. Mol Gen Genet (1975) 8.80
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 6.16
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell (1990) 6.08
Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 5.95
Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science (1995) 4.55
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J (1994) 4.37
The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature (1988) 4.33
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J (1995) 4.17
Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J (1992) 4.00
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature (1992) 3.78
Analysis of sequences transposed by complementation of two classes of transposition-deficient mutants of Tn3. J Bacteriol (1978) 3.69
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (1998) 3.67
A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J (1991) 3.64
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol (1998) 3.58
Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J (1989) 3.51
Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature (1986) 3.41
Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature (1990) 3.29
Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature (1991) 3.10
Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature (1983) 3.09
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr Biol (1994) 3.06
Dynamic fatty acylation of p21N-ras. EMBO J (1987) 2.99
Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A (1988) 2.99
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature (1985) 2.90
False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol (1997) 2.84
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol (1995) 2.82
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J (2001) 2.66
Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J (1995) 2.51
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 2.47
Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol (1998) 2.33
rho family GTPase activating proteins p190, bcr and rhoGAP show distinct specificities in vitro and in vivo. EMBO J (1993) 2.31
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res (1991) 2.30
DNA in medicine. Oncogenes. Lancet (1984) 2.28
Polypeptides expressed in Escherichia coli K-12 minicells by transposition elements Tn1 and Tn3. J Bacteriol (1979) 2.17
Post-translational modifications of p21rho proteins. J Biol Chem (1992) 2.17
Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry (2007) 2.10
Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J (1991) 2.09
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst (1977) 2.07
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science (1998) 2.06
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut (1997) 2.00
Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet (1987) 1.99
Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem (2000) 1.88
Mesoderm induction in Xenopus caused by activation of MAP kinase. Nature (1995) 1.86
Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice. J Virol (1980) 1.85
Computer simulation model of an x-ray department. Br Med J (1972) 1.80
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. J Biol Chem (1993) 1.79
Identification of the ferroxidase centre in ferritin. FEBS Lett (1989) 1.78
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77
Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer (1975) 1.77
Structure, function, and evolution of ferritins. J Inorg Biochem (1992) 1.77
Enhanced post-irradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents. Cell Tissue Kinet (1978) 1.76
Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv (1996) 1.74
A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem (1993) 1.74
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res (1994) 1.71
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
A transforming gene present in human sarcoma cell lines. Nature (1982) 1.67
Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem (2000) 1.66
Biochemical and biological properties of the human N-ras p21 protein. Mol Cell Biol (1987) 1.65
Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry (2006) 1.64
Chromosome rearrangements for the control of insect pests. Science (1972) 1.61
Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. EMBO J (1984) 1.56
Induction of endogenous and of spleen focus-forming viruses during dimethylsulfoxide-induced differentiation of mouse erythroleukemia cells transformed by spleen focus-forming virus. Proc Natl Acad Sci U S A (1975) 1.55
Application of lipovitellin-salt-mannitol agar for screening, isolation, and presumptive identification of Staphylococcus aureus in a teaching hospital. J Clin Microbiol (1996) 1.55
Scrape-loading of Swiss 3T3 cells with ras protein rapidly activates protein kinase C in the absence of phosphoinositide hydrolysis. Oncogene (1989) 1.50
Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer (1978) 1.48
The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action. FEBS Lett (1994) 1.47
Transformation and stimulation of DNA synthesis in NIH-3T3 cells are a titratable function of normal p21N-ras expression. EMBO J (1986) 1.46
Activated ras oncogenes in human thyroid cancers. Cancer Res (1988) 1.45
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia (2006) 1.45
The influence of the MAPK pathway on T cell lineage commitment. Immunity (1997) 1.43
Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J Biol Chem (1993) 1.43
Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol (1997) 1.41
Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene (1999) 1.41
Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet (1978) 1.40
CLINICAL EXPERIENCES WITH PERCAIN, A NEW LOCAL ANAESTHETIC. Br Med J (1930) 1.40
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature (1984) 1.40
Cost savings controversy. J Ophthalmic Nurs Technol (1991) 1.39
The urease ELISA for H-Y antibody. A cautionary tale. J Immunol Methods (1990) 1.38
Maintenance of long-term potentiation in rat dentate gyrus requires protein synthesis but not messenger RNA synthesis immediately post-tetanization. Neuroscience (1989) 1.37
Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol (2001) 1.37
Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems. Oncogene (1988) 1.37
Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol (1999) 1.37
p21H-ras-induced morphological transformation and increases in c-myc expression are independent of functional protein kinase C. EMBO J (1989) 1.36
A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. Oncogene (1988) 1.35
A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res (1986) 1.33
p21ras couples the T cell antigen receptor to extracellular signal-regulated kinase 2 in T lymphocytes. J Exp Med (1993) 1.32
Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol Cell Biol (1993) 1.31
Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. J Biol Chem (1997) 1.31
Evidence that a salt bridge in the light chain contributes to the physical stability difference between heavy and light human ferritins. J Biol Chem (1992) 1.30
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci U S A (1986) 1.29
The performance of routine ultrasonographic screening of pregnancies in the Eurofetus Study. Am J Obstet Gynecol (1999) 1.27
Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood (1992) 1.27